Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement

por Giorgino, Francesco, Penfornis, Alfred, Pechtner, Valeria, Gentilella, Raffaella, Corcos, Antonella
Publicado 2018

Changing the approach to type 2 diabetes treatment: A comparison of glucagon‐like peptide‐1 receptor agonists and sulphonylureas across the continuum of care

por Orsini Federici, Marco, Gentilella, Raffaella, Corcos, Antonella, Torre, Enrico, Genovese, Stefano
Publicado 2021

Change in HbA(1c) Across the Baseline HbA(1c) Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents

por Gentilella, Raffaella, Romera, Irene, Nicolay, Claudia, Buzzetti, Raffaella, Vázquez, Luis Alberto, Sesti, Giorgio
Publicado 2019

Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes

por Matza, Louis S, Boye, Kristina S, Jordan, Jessica B, Norrbacka, Kirsi, Gentilella, Raffaella, Tiebout, Amara R, Browne, Chantelle, Orsini Federici, Marco, Biricolti, Giovanni, Stewart, Katie D
Publicado 2018

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics

por García-Pérez, Luis-Emilio, Boye, Kristina S., Rosilio, Myriam, Jung, Heike, Heitmann, Elke, Norrbacka, Kirsi, Federici, Marco Orsini, Gentilella, Raffaella, Guerci, Bruno, Giorgino, Francesco, Aigner, Ulrich, Sapin, Hélène
Publicado 2021